BGLC
BioNexus Gene Lab Corp.·Healthcare
2.18
3.081%(−0.07)
Market ClosedLast Updated: — ET
52W L: $1.9252W H: $15.60
BGLC NEWS
globenewswire.com
Mar 11
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelion is a precision diagnostics company focused on advancing next-generation oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays. Fidelion serves as the international intellectual property and commercialization vehicle for the VitaGuard™ MRD technology developed by Tongshu Gene, supporting commercialization initiatives outside Greater China. BGLC is a strategic investor in Fidelion and holds exclusive commercialization rights for VitaGuard™ across Southeast Asia through its licensing arrangement with Fidelion.
globenewswire.com
Feb 23
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. (“Chemrex”).
defenseworld.net
Feb 22
Financial Comparison: Beauty Health (NASDAQ:SKIN) vs. BioNexus Gene Lab (NASDAQ:BGLC)
BioNexus Gene Lab (NASDAQ: BGLC - Get Free Report) and Beauty Health (NASDAQ: SKIN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Risk and Volatility BioNexus Gene Lab
defenseworld.net
Feb 21
BioNexus Gene Lab (NASDAQ:BGLC) Stock Price Up 1.7% – Still a Buy?
BioNexus Gene Lab Corp. (NASDAQ: BGLC - Get Free Report) was up 1.7% during trading on Friday. The stock traded as high as $2.45 and last traded at $2.43. Approximately 13,358 shares were traded during trading, a decline of 73% from the average daily volume of 49,084 shares. The stock had previously closed at $2.39.
globenewswire.com
Jan 28
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market
KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform. This phase marks the transition of VitaGuard™ from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacy monitoring systems throughout Southeast Asia.
